Shandong Boan Biotechnology Co. Ltd., a joint stock company based in the People's Republic of China, has announced the placement of 38,400,000 new shares under a general mandate. This represents approximately 7.17% of the company's total shares in issue. The company has entered into an agreement with a Placing Agent to facilitate the sale of these new shares on a best effort basis. The initiative is part of the company's strategy to raise capital and strengthen its financial position. The shares are listed on the Main Board of the Stock Exchange of Hong Kong, under the stock code 6955.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。